U.S., Dec. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07272811) titled 'Neurocognitive Assessment Platform 4 Alzheimer' on Nov. 26.
Brief Summary: The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050. In Italy, there are approximately 1.2 million cases of dementia, with 600,000 attributed to AD. Given the limited effectiveness of current pharmacological treatments, there is a growing need for early, non-pharmacological interventions to slow disease progression and improve the quality of life for patients and caregivers.
The Neurocognitive Assessment Platform 4 Alzheimer ...